Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

Приверженность терапии и фиксированные комбинации при лечении артериальной гипертензии. Фокус на фиксированную комбинацию фелодипина и метопролола

Полный текст:

Аннотация

Статья посвящена весьма актуальному в настоящее время вопросу — применению фиксированных комбинаций лекарственных препаратов для лечения артериальной гипертонии (АГ), как одному из успешных методов повышения приверженности больных АГ лечению.

Об авторах

С. А. Шальнова
ФГУ Государственный научно-исследовательский центр профилактической медицины Росмедтехнологии
Россия

Заместитель директора по науке, руководитель отдела эпидемиологии неинфекционных заболеваний.

Москва



С. К. Кукушкин
ФГУ Государственный научно-исследовательский центр профилактической медицины Росмедтехнологии
Россия

Ведущий научный сотрудник отдела эпидемиологии неинфекционных заболеваний.

Москва



Е. М. Маношкина
ФГУ Государственный научно-исследовательский центр профилактической медицины Росмедтехнологии
Россия

Старший лаборант с высшим образованием кафедры госпитальной терапии №2 леч. факультетата МГМСУ.

Москва



Список литературы

1. Guidelines Subcommittee of the WHO-ISH. 1999 World Health Organization — International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.

2. Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure. The sixth report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 1997; 157 (21): 2413-46.

3. 2007 Guidelines for the management of Arterial hypertension. J Hypertens 2007; 25: 1105-87.

4. Национальные клинические рекомендации. Диагностика и лечение артериальной гипертензии. М.: “Силицея-Полиграф” 2008.

5. Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006; 47: 345-51.

6. Claxon AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-310.

7. Domino FJ. Improving adherence to treatment of hypertension. Am Fam Physician 2005; 71: 2089-90.

8. Schroeder K, Fahey TK, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized control trails. Arch Intern Med 2004; 164: 722-32.

9. Mitka M. Research probes details of poor adherence in antihypertension drug therapy JAMA 2007; 298: 2128.

10. Feldman R, Zou G, Vavdervoort, et al. A simplified approach to the treatment of uncomplicated hypertension/ A cluster randomized, controlled trail. Hypertens 2009; 53: 646-53.

11. Neutel JB. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin 2008; 24: 2389-401.

12. Bangalore S, Kamalallannan G, Parkar S, Messerli FH. Fixed- dose combinations improve medication adherence: a metaanalysis. Am J Med 2008; 120: 713-9.

13. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5: 561-72.

14. Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension. Mortality results grom the MAPHY study. JAMA 1988; 259(13): 1976-82.

15. MERIT-HF Study Group. Effect ofmetoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.

16. Hedblad В, Wikslrand J, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness (IMT): main results from the Beta-blocker Cholester ol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-6.

17. Wiklund O, Hulthe J, Wlkstrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year ran¬domized study. Stroke 2002; 33: 572-7.

18. Hansson L, Zanchetti A, for the HOT study Group. The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability. Blood Press 1997; 6: 313-7.

19. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with. Circulation 1997; 96: 856-63 enalapril. V-Heft III

20. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.

21. Dahlof В, Hosie J. Antihypertensive efficacy and tolerability of a new once-daily felodipine-metoprolol combination compared with each component alone. Blood Press 1993; 2 Suppl. 1: 22-9.

22. Trenkwalder P, Elmfeldt D. Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs — the rationale and benefits of combining felodipine and metoprolol. J Hum Hypertens 1995; 9 Suppl. 2: 37-42.

23. Siewert-Delle A, Ljungman S, Hartford M. Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension: addition of felodipine or ramipril to long-term treatment with beta-blockade. Am J Hypertens 1995; 8: 113-23.

24. Dahlof В, Pennert К, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.

25. Freeling P, Davis RH, Goves JR, et al. Control of hypertension in elderly patients with felodipine and metoprolol: a double blind, placebo-controlled clinical trial. Br J Clin Pharmacol 1987; 24: 459-64.

26. Jennings GL, Sudhir K, Laufer E. Assessment of effects of two anti-hypertensive regimens on overall cardiovascular risk. J Hum Hypertens 1995; 9: 181-6.

27. Missault LH, Friart A, Van BP. Efficacy, tolerability and quality of life in the Hypertension Optimal Reduction by Treatment Adjustments — trial (abstract). Cardiovasc Drugs Ther 1999; 13:68.

28. Dahlof B, Jonsson L, Borgholst 0, et al. Improved antihypertensive efficacy of the felodipine-metoprolol extended-release tablet compared with each drug alone. Blood Press 1993; 2 Suppl. 1: 37-45.

29. Dahlof В, Hosie J. Antihypertensive efficacy and tolerability of a fixed combination of metoprolol and felodipine in comparison with the individual substances in monotherapy. J Car diovasc Pharmacol 1990; 16: 910-6.

30. Klein G, German MC, Study Group. Combination therapy with felodipine and metoprolol compared with captopril and hydrochlorothiazide. Blood Press 1998; 7: 308-12.

31. Berger A, Chima P, Dawes M, et al. A fixed combination of felodipine 5mg and metoprolol 50mg compared with double doses of the individual components as antihypertensive therapy. J Drug Dev 1992; 4: 199-206.

32. Hosie J, DahlofB, Klein G. The long-term antihypertensive efficacy and safety of a new felodipine-metoprolol combination tablet. Blood Press 1993; 2 Suppl 1: 46-50.

33. Todd PA, Faulds D. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs 1992; 44: 251-77.

34. Hoffmann J. Comparison of a felodipine-metoprolol combination tablet vs each component alone as antihypertensive therapy. Blood Press 1993; 2 Suppl. 1: 30-6.

35. Andersson F, Kartman B, Andersson OK. Cost-effectiveness of felodipine-metoprolol (Logimax) and enalapril in the treatment of hypertension. Clin Exp Hypertens 1998; 20: 833-46.

36. Glasgow RE, Emmons KM. How we can increase translation of research into practice? Type of evidence needed. Ann Rev Publ Health 2007; 28: 413-33.

37. Frankle AL, Smit MC, de Veer AJE, Mistiaen P. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Making 2008; 8: 38 (1-11).


Для цитирования:


Шальнова С.А., Кукушкин С.К., Маношкина Е.М. Приверженность терапии и фиксированные комбинации при лечении артериальной гипертензии. Фокус на фиксированную комбинацию фелодипина и метопролола. Кардиоваскулярная терапия и профилактика. 2009;8(6):77-81.

For citation:


Shalnova S.A., Kukushkin S.K., Manoshkina E.M. Therapy compliance and fixed-dose combinations in arterial hypertension treatment. Focus on a fixed-dose combination of felodipine and metoprolol. Cardiovascular Therapy and Prevention. 2009;8(6):77-81. (In Russ.)

Просмотров: 36


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)